Managers

The current private equity fundraising environment is proving challenging for LPs and GPs alike, with limited timeframes and ever-larger funds creating gridlock.

The presence of a US public pension system as a lead investor is a reflection of the growing sophistication and the desire on the part of some big US public plans to take more direct roles in investment management.

Where a lot of private equity firms struggle is the sheer amount of data they’re presented during diligence, often dealing with fragmented insights into a company’s operations.

TaylorMade was buried in the bunker until KPS made a brilliant sand save.

Accel-KKR saw that Seequent’s geological scanning software could dig much deeper than first thought, with far more applications possible.

Scalpel! Francisco’s carve-out of Capsule Technologies, which provides patient monitoring and medical device integration, was just what the doctor ordered.

We toast the work of six private equity firms for their highly successful deals made in 2021. Francisco Partners takes the top prize with its carve-out of medical device maker Capsule Technologies.

The scale of the firm’s Belron deal set the bar high for GP-led single asset deals. And it’s clear as glass that GPs will be looking to beat it.

EQT sold Aldevron for $9.6bn just 22 months after buying the maker of mRNA vaccine components for $3.4bn.

Argosy transforms Paragon from niche player in the nuclear power sector to predominant force.